Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

ALG-055009, a Novel Thyroid Hormone Receptor Beta (THR-β) Agonist, was Well-tolerated with Significant Reductions in Liver Fat at Week 12 in Non-cirrhotic MASH Patients in the Randomized, Double-Blind, Placebo-controlled Phase 2a HERALD Study

Friday, March 28, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The Phase 2a HERALD study demonstrated that ALG-055009, a novel THR-β agonist, was well-tolerated and resulted in significant reductions in liver fat after 12 weeks in non-cirrhotic MASH patients. This randomized, double-blind, placebo-controlled trial highlights the potential of ALG-055009 in treating liver fat accumulation.
Price reaction · baseline $9.12 (2025-03-28 close) · hit after-hours · clean, no other ALGS news in the window
day 0 close
-9.5%
day 1
-21.7%
day 3 · peak
-28.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • ALG-055009 showed significant reductions in liver fat.
  • The treatment was well-tolerated among patients.
  • The study was conducted in a randomized, double-blind manner.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What is ALG-055009?

ALG-055009 is a novel thyroid hormone receptor beta (THR-β) agonist.

What were the results of the HERALD study?

The HERALD study showed significant reductions in liver fat after 12 weeks.

How was the HERALD study designed?

It was a randomized, double-blind, placebo-controlled trial.

Who were the participants in the study?

The study involved non-cirrhotic patients with MASH.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare ALG-055009 THR-β agonist MASH Phase 2a study liver fat
Last updated: Mar 28, 2025

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →